Your browser doesn't support javascript.
loading
Bacille Calmette-Guérin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro.
Diray-Arce, Joann; Angelidou, Asimenia; Jensen, Kristoffer Jarlov; Conti, Maria Giulia; Kelly, Rachel S; Pettengill, Matthew A; Liu, Mark; van Haren, Simon D; McCulloch, Scott D; Michelloti, Greg; Idoko, Olubukola; Kollmann, Tobias R; Kampmann, Beate; Steen, Hanno; Ozonoff, Al; Lasky-Su, Jessica; Benn, Christine S; Levy, Ofer.
Afiliação
  • Diray-Arce J; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: joann.arce@childrens.harvard.edu.
  • Angelidou A; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Jensen KJ; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, University of Southern Denmark, 2300 Copenhagen, Denmark; Bandim Health Project, Department of Clinical Research, University of Southern Denmark, 1455 Copenhagen K, Denmark; Experimental and Translational Immunology, Departmen
  • Conti MG; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Maternal and Child Health, Sapienza University of Rome, 00185 Rome, Italy.
  • Kelly RS; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Pettengill MA; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Liu M; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • van Haren SD; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
  • McCulloch SD; Metabolon, Morrisville, NC 27560, USA.
  • Michelloti G; Metabolon, Morrisville, NC 27560, USA.
  • Idoko O; The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Kollmann TR; Telethon Kids Institute, University of Western Australia, Perth, WA 6009, Australia.
  • Kampmann B; The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Steen H; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Ozonoff A; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
  • Lasky-Su J; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Benn CS; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, University of Southern Denmark, 2300 Copenhagen, Denmark; Bandim Health Project, Department of Clinical Research, University of Southern Denmark, 1455 Copenhagen K, Denmark; Danish Institute for Advanced Study, University of S
  • Levy O; Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
Cell Rep ; 39(5): 110772, 2022 05 03.
Article em En | MEDLINE | ID: mdl-35508141
ABSTRACT
Vaccines have generally been developed with limited insight into their molecular impact. While systems vaccinology enables characterization of mechanisms of action, these tools have yet to be applied to infants, who are at high risk of infection and receive the most vaccines. Bacille Calmette-Guérin (BCG) protects infants against disseminated tuberculosis (TB) and TB-unrelated infections via incompletely understood mechanisms. We employ mass-spectrometry-based metabolomics of blood plasma to profile BCG-induced infant responses in Guinea-Bissau in vivo and the US in vitro. BCG-induced lysophosphatidylcholines (LPCs) correlate with both TLR-agonist- and purified protein derivative (PPD, mycobacterial antigen)-induced blood cytokine production in vitro, raising the possibility that LPCs contribute to BCG immunogenicity. Analysis of an independent newborn cohort from The Gambia demonstrates shared vaccine-induced metabolites, such as phospholipids and sphingolipids. BCG-induced changes to the plasma lipidome and LPCs may contribute to its immunogenicity and inform the development of early life vaccines.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Vacina BCG Limite: Humans / Infant / Newborn Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Vacina BCG Limite: Humans / Infant / Newborn Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article